欧美成人动漫日韩国庆_亚洲天堂自拍偷拍_人妻少妇边接电话边娇喘_新婚少妇交换杨雨婷_高清不卡一区二区在线观看_亚洲国产中文另类久久久精品网站_十八禁裸体自慰免费观看_日本亚洲中文有码_日本人zzzwww色视频直播_国产福利姬在线观看

d3-pcbanner-33.jpg d3-phbanner.jpg
Clinical Trials
A Randomized, Single blind, Placebo Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD4059 in Healthy Subjects

“A Randomized, Single-Blind, Placebo-Controlled Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses of Subcutaneously Administered RBD5044 in Healthy Subjects”, this study is ongoing in Australia. the study is currently in the single-dose incremental enrolment phase.

RBD4059 is a GalNAc-siRNA drug that inhibits FXI activity and prolongs APTT to achieve anticoagulant effects. As demonstrated in preclinical data, RBD4059 has a long-lasting and potent antithrombotic effect combined with a favorable safety profile. RBD4059 is the first FXI targeting siRNA drug that that has entered the clinical stage.

聯系

如果您想了解更多關于本研究或研究藥物的信息,歡迎聯系項目負責人,她(他)將更為詳細的為您介紹本項目,并安排您進行相應的檢查。

石瑩
ying.shi@smo-clinplus.com
冒建培
ianpei.mao@smo-clinplus.com
胡金慧
jinhui.hu@smo-clinplus.com